Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscular Atrophy, Spinal | 3 | 2023 | 47 | 0.400 |
Why?
|
| Colitis, Ulcerative | 3 | 2022 | 211 | 0.400 |
Why?
|
| Crohn Disease | 3 | 2022 | 292 | 0.380 |
Why?
|
| Escherichia coli | 5 | 2022 | 991 | 0.370 |
Why?
|
| Enterobacteriaceae | 2 | 2020 | 40 | 0.290 |
Why?
|
| Point-of-Care Testing | 3 | 2022 | 33 | 0.250 |
Why?
|
| United Kingdom | 6 | 2021 | 267 | 0.230 |
Why?
|
| Enterobacteriaceae Infections | 3 | 2020 | 60 | 0.220 |
Why?
|
| Animal Diseases | 1 | 2023 | 8 | 0.200 |
Why?
|
| Animals, Wild | 1 | 2023 | 32 | 0.200 |
Why?
|
| Mitochondrial Myopathies | 1 | 2023 | 28 | 0.190 |
Why?
|
| Escherichia coli Infections | 2 | 2022 | 198 | 0.190 |
Why?
|
| Carbapenems | 2 | 2020 | 47 | 0.180 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2022 | 34 | 0.180 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2022 | 70 | 0.180 |
Why?
|
| Whole Genome Sequencing | 3 | 2020 | 362 | 0.180 |
Why?
|
| Plasmids | 2 | 2020 | 449 | 0.180 |
Why?
|
| Medical Informatics | 1 | 2023 | 107 | 0.170 |
Why?
|
| Hepatitis B | 1 | 2023 | 171 | 0.170 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2023 | 238 | 0.170 |
Why?
|
| Motor Neurons | 2 | 2023 | 131 | 0.170 |
Why?
|
| beta-Lactamases | 2 | 2020 | 211 | 0.160 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2020 | 5 | 0.160 |
Why?
|
| Genome, Bacterial | 2 | 2020 | 200 | 0.160 |
Why?
|
| Bacteremia | 3 | 2018 | 446 | 0.160 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 139 | 0.150 |
Why?
|
| DNA, Bacterial | 2 | 2020 | 481 | 0.150 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 7 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2022 | 285 | 0.140 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 525 | 0.140 |
Why?
|
| Acinetobacter baumannii | 1 | 2019 | 42 | 0.140 |
Why?
|
| Bacterial Proteins | 4 | 2020 | 953 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 327 | 0.140 |
Why?
|
| Colistin | 1 | 2018 | 32 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 5 | 2022 | 2596 | 0.130 |
Why?
|
| Carrier State | 1 | 2018 | 80 | 0.130 |
Why?
|
| Blood Culture | 1 | 2018 | 44 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 401 | 0.130 |
Why?
|
| Ribonucleoproteins | 1 | 2017 | 56 | 0.120 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 157 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 639 | 0.120 |
Why?
|
| Molecular Chaperones | 1 | 2017 | 172 | 0.120 |
Why?
|
| Hospitalization | 2 | 2021 | 1950 | 0.110 |
Why?
|
| Humans | 26 | 2023 | 131163 | 0.110 |
Why?
|
| Pandemics | 4 | 2022 | 1118 | 0.100 |
Why?
|
| Quality of Life | 1 | 2023 | 2082 | 0.100 |
Why?
|
| Livestock | 2 | 2023 | 12 | 0.100 |
Why?
|
| Kenya | 2 | 2023 | 60 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2020 | 859 | 0.080 |
Why?
|
| Streptolysins | 2 | 2001 | 9 | 0.080 |
Why?
|
| Dexamethasone | 2 | 2023 | 250 | 0.080 |
Why?
|
| Biomarkers | 1 | 2020 | 3385 | 0.080 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2001 | 88 | 0.080 |
Why?
|
| Intensive Care Units | 2 | 2022 | 526 | 0.070 |
Why?
|
| Hospitals | 2 | 2021 | 435 | 0.070 |
Why?
|
| Pneumococcal Infections | 2 | 2001 | 281 | 0.070 |
Why?
|
| Middle Aged | 8 | 2023 | 28601 | 0.060 |
Why?
|
| Male | 10 | 2023 | 64957 | 0.060 |
Why?
|
| Child | 6 | 2022 | 26341 | 0.050 |
Why?
|
| Urbanization | 1 | 2023 | 10 | 0.050 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 2023 | 10 | 0.050 |
Why?
|
| Cities | 1 | 2023 | 51 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2023 | 99 | 0.050 |
Why?
|
| Neuromuscular Junction | 1 | 2023 | 87 | 0.050 |
Why?
|
| Biodiversity | 1 | 2023 | 73 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 60 | 0.050 |
Why?
|
| Ecosystem | 1 | 2023 | 91 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2023 | 101 | 0.050 |
Why?
|
| Female | 9 | 2023 | 70963 | 0.050 |
Why?
|
| Adult | 7 | 2022 | 31282 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 158 | 0.050 |
Why?
|
| Azo Compounds | 1 | 2022 | 14 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 191 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 133 | 0.040 |
Why?
|
| Respiratory System | 1 | 2022 | 94 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 109 | 0.040 |
Why?
|
| Dependovirus | 1 | 2022 | 160 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2020 | 6459 | 0.040 |
Why?
|
| Prevalence | 2 | 2019 | 2701 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 1 | 2001 | 52 | 0.040 |
Why?
|
| State Medicine | 1 | 2021 | 23 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2001 | 786 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6797 | 0.040 |
Why?
|
| Metagenomics | 1 | 2022 | 116 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 14 | 0.040 |
Why?
|
| Triage | 1 | 2022 | 144 | 0.040 |
Why?
|
| Clavulanic Acid | 1 | 2020 | 7 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 2 | 2001 | 389 | 0.040 |
Why?
|
| Smokers | 1 | 2020 | 48 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 5063 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 301 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 83 | 0.040 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 1999 | 5 | 0.040 |
Why?
|
| Laos | 1 | 2019 | 6 | 0.040 |
Why?
|
| Klebsiella Infections | 1 | 2020 | 57 | 0.040 |
Why?
|
| Metabolome | 1 | 2022 | 326 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 43 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1626 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 416 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2022 | 892 | 0.040 |
Why?
|
| Acinetobacter Infections | 1 | 2019 | 31 | 0.040 |
Why?
|
| Aged | 4 | 2021 | 21025 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2022 | 446 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 414 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2001 | 406 | 0.040 |
Why?
|
| Metabolomics | 1 | 2022 | 501 | 0.030 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2018 | 52 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2023 | 981 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 501 | 0.030 |
Why?
|
| SMN Complex Proteins | 1 | 2017 | 7 | 0.030 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2017 | 16 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2018 | 135 | 0.030 |
Why?
|
| China | 1 | 2018 | 278 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 2018 | 82 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 1410 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 166 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 154 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 1176 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2022 | 807 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2023 | 12936 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2017 | 166 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 146 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 541 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2018 | 319 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2020 | 15110 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1240 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1489 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 2304 | 0.030 |
Why?
|
| Actins | 1 | 2017 | 321 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 1421 | 0.030 |
Why?
|
| Prognosis | 2 | 2021 | 4886 | 0.030 |
Why?
|
| Feces | 1 | 2018 | 721 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 483 | 0.030 |
Why?
|
| Time Factors | 2 | 2020 | 6196 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1224 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 650 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2021 | 844 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3359 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 533 | 0.020 |
Why?
|
| Animals | 3 | 2023 | 33912 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 1692 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2885 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 2550 | 0.020 |
Why?
|
| Adolescent | 2 | 2020 | 20987 | 0.020 |
Why?
|
| Phenotype | 1 | 2020 | 4497 | 0.020 |
Why?
|
| Infant | 2 | 2019 | 13352 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 17753 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 92 | 0.010 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2001 | 65 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2001 | 164 | 0.010 |
Why?
|
| Virulence | 1 | 2001 | 268 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2000 | 144 | 0.010 |
Why?
|
| Serotyping | 1 | 1999 | 170 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 1999 | 106 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 787 | 0.010 |
Why?
|
| Eye | 1 | 1999 | 215 | 0.010 |
Why?
|
| Phylogeny | 1 | 1999 | 689 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1999 | 1447 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 2085 | 0.010 |
Why?
|
| Risk Factors | 1 | 2000 | 11074 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 18301 | 0.000 |
Why?
|